Clinical trial · Observational
HPV-test, Cervical Cancer and Follow-up
Recurrence After Surgery for Cervical Cancer - an Evaluation of the Follow-up Program.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators have planned this project to evaluate the follow-up program after surgery due to cervical cancer and to explore the possibilities for different tests of Human Papilloma Virus (HPV) in contributing to the customization of the follow-up program. Purpose: The investigators effort is to provide the background for an evidence-based update of the follow-up program after surgery due to cervical cancer with the purpose of early diagnosis of recurrence affecting quality of life for as few women as possible.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Human Papilloma Virus | — | UNRESOLVED | — |
| Recurrence | — | UNRESOLVED | — |
| Uterine Cervical Neoplasms | Cervical Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Human Papilloma Virus test from the vaginal vault | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Human Papilloma Virus test
- description
- Patients treated with surgery alone for uterine cervical neoplasms attending surveillance at Dept. of Obstetrics and Gynecology, Oncogynecological unit, Aarhus University Hospital from 01.01.14 From 01.01.15 patients will be recruited from Oncogynecologic units at Aalborg University Hospital and Rigshospitalet. Recruitment of patients from these institutions has not been successful and has been closed. It is expected due to political decisions that the cervical cancer patients from the uptake area of Aalborg University Hospital will be treated at Aarhus University Hospital and they will then be eligible for the study
- interventionNames
- Procedure: Human Papilloma Virus test from the vaginal vault
Primary outcomes (1)
- measure
- Prevalence of HPV Genotypes in Vagina (Type 16, 18 and Other)
- timeFrame
- 2 years
Secondary outcomes (1)
- measure
- HPV Clearance From Vagina in Between the Two Planned Follow-up Visits.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Surgery. FIGO stage IA-IB. \> 18 years Exclusion Criteria: * Ajuvant oncologic treatment
References
Publications (0)
Data not yet available